Last $7.09 USD
Change Today -0.165 / -2.28%
Volume 737.2K
PGNX On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 3:18 PM 12/22/14 All times are local (Market data is delayed by at least 15 minutes).

progenics pharmaceuticals (PGNX) Snapshot

Open
$7.11
Previous Close
$7.25
Day High
$7.43
Day Low
$7.01
52 Week High
12/18/14 - $7.57
52 Week Low
05/9/14 - $3.10
Market Cap
492.5M
Average Volume 10 Days
1.5M
EPS TTM
$0.07
Shares Outstanding
69.6M
EX-Date
--
P/E TM
95.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for PROGENICS PHARMACEUTICALS (PGNX)

progenics pharmaceuticals (PGNX) Related Businessweek News

No Related Businessweek News Found

progenics pharmaceuticals (PGNX) Details

Progenics Pharmaceuticals, Inc. develops medicines for oncology. The company offers Relistor-subcutaneous injection for the treatment of opioid induced constipation (OIC) in advanced-illness patients receiving palliative care when laxative therapy has not been sufficient; and for treatment of OIC inpatients with non-cancer pain. It also develops Relistor-oral that is in Phase III testing for the treatment of OIC. In addition, the company’s clinical-stage product candidates include prostate specific membrane antigen (PSMA) antibody-drug conjugate, which has completed Phase II testing in chemotherapy-experienced patients and is ongoing second cohort in chemotherapy-naïve patients for the treatment of prostate cancer; 1404, a radio-labeled small molecule that has completed Phase II testing, as well as acts as an imaging agent to diagnose and detect prostate cancer; and Azedra, a radiotherapeutic product candidate, which is in Phase IIb registrational trial under special protocol assessment for the treatment of pheochromocytoma and paraganglioma. Further, it develops MIP-1095, a PSMA-targeted small molecule radiopharmaceutical that is in clinical development stage for the treatment of prostate cancer. The company has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide other than Japan; and collaboration agreement with Seattle Genetics, Inc. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in Tarrytown, New York.

69 Employees
Last Reported Date: 03/13/14
Founded in 1986

progenics pharmaceuticals (PGNX) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: $535.6K
Principal Financial Officer, Principal Accoun...
Total Annual Compensation: $279.6K
Executive Vice President of Medical Affairs
Total Annual Compensation: $426.5K
Senior Vice President of Manufacturing
Total Annual Compensation: $296.5K
Vice President of Regulatory Affairs
Total Annual Compensation: $341.5K
Compensation as of Fiscal Year 2013.

progenics pharmaceuticals (PGNX) Key Developments

Progenics Pharmaceuticals, Inc. Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-19-2014 01:40 PM

Progenics Pharmaceuticals, Inc. Presents at Jefferies 2014 Global Healthcare Conference: London, Nov-19-2014 01:40 PM. Venue: The Waldorf Hilton, Aldwych, London, United Kingdom. Speakers: Mark R. Baker, Chief Executive Officer, Director and Member of Science & Strategy Committee.

Progenics Pharmaceuticals, Inc. Presents at Stifel Healthcare Conference 2014, Nov-18-2014 02:25 PM

Progenics Pharmaceuticals, Inc. Presents at Stifel Healthcare Conference 2014, Nov-18-2014 02:25 PM. Venue: The Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Mark R. Baker, Chief Executive Officer, Director and Member of Science & Strategy Committee.

Progenics Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Reports Intangible Impairment Charges for the Third Quarter Ended September 30, 2014

Progenics Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total revenues of $41,656,000 against $867,000 a year ago. Operating income was $36,736,000 against operating loss of $10,512,000 a year ago. Net income before income tax benefit was $36,748,000 against net loss before income tax benefit of $10,500,000 a year ago. Net income was $36,975,000 or $0.51 per diluted share against net loss of $10,500,000 or $0.17 per share a year ago. The revenue was up from 2013, reflecting an increase in collaboration revenue of $39.9 million, primarily resulting from the recognition of the $40 million milestone from Salix. For the nine months, the company reported total revenue of $44,948,000 against $4,894,000 a year ago. Operating income was $16,324,000 against operating loss of $34,057,000 a year ago. Net income before income tax benefit was $16,361,000 against net loss before income tax benefit of $34,021,000 a year ago. Net income was $16,589,000 or $0.24 per diluted share against net loss of $34,021,000 or $0.63 per share a year ago. For the third quarter, the company reported intangible impairment charges of $576,000.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PGNX:US $7.08 USD -0.17

PGNX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Array BioPharma Inc $4.81 USD -0.055
CTI BioPharma Corp $2.41 USD -0.03
Dynavax Technologies Corp $15.07 USD -0.27
Inovio Pharmaceuticals Inc $9.38 USD -0.10
ZIOPHARM Oncology Inc $4.75 USD -0.05
View Industry Companies
 

Industry Analysis

PGNX

Industry Average

Valuation PGNX Industry Range
Price/Earnings 59.5x
Price/Sales 10.5x
Price/Book 3.7x
Price/Cash Flow 58.5x
TEV/Sales 8.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PROGENICS PHARMACEUTICALS, please visit www.progenics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.